- Home
- SYBT vs ZLAB Comparison
SYBT vs ZLAB Comparison
Compare SYBT & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SYBT | ZLAB |
|---|---|---|
| Founded | 1904 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | SYBT | ZLAB |
|---|---|---|
| Price | $67.15 | $17.95 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $83.67 | $57.22 |
| AVG Volume (30 Days) | 187.0K | ★ 989.7K |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | ★ 26.16 | N/A |
| EPS | ★ 4.58 | N/A |
| Revenue | $378,633,000.00 | ★ $441,629,000.00 |
| Revenue This Year | $17.26 | $30.20 |
| Revenue Next Year | $5.29 | $34.71 |
| P/E Ratio | $14.98 | ★ N/A |
| Revenue Growth | 14.11 | ★ 24.14 |
| 52 Week Low | $60.75 | $16.82 |
| 52 Week High | $83.83 | $44.34 |
Technical Indicators
Market Signals| Indicator | SYBT | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.40 | 31.15 |
| Support Level | $67.57 | $16.82 |
| Resistance Level | $69.87 | $18.67 |
| Average True Range (ATR) | 1.59 | 0.60 |
| MACD | 0.06 | 0.13 |
| Stochastic Oscillator | 15.43 | 33.53 |
Price Performance
Historical ComparisonAbout SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and Trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates the majority of its revenue from the Commercial Banking segment.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.